Trial Profile
A Phase 2, Randomized, Open-Label Active-Comparator (Epoetin Alfa) and Single-Blind Placebo-Controlled, Dose-Ranging Safety and Exploratory Efficacy Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Jan 2022
Price :
$35
*
At a glance
- Drugs Roxadustat (Primary) ; Epoetin alfa
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors FibroGen
- 16 Feb 2016 Results published in a FibroGen media release.
- 18 Sep 2014 New trial record